Efficacy of Vastarel MR on silent and symptomatic myocardial ischemia

Giuseppe Camitini, Giuseppe Marazzi, Giuseppe Rosano

Research output: Contribution to journalArticle

Abstract

Despite advances in the medical treatment of myocardial ischemia, a large proportion of patients with coronary artery disease suffer from angina and have silent episodes of myocardial ischemia. Chronic repetitive ischemic episodes may lead to ischemic cardiomyopathy. Trimetazidine, the 3-ketoacyl coenzyme A thiolase inhibitor, is a metabolically active agent that is effective, whether alone or in combination with standard therapy, in reducing myocardial ischemia. It has been shown to reduce daily episodes of both silent and symptomatic myocardial ischemia. These effects, together with those of trimetazidine on myocardial energy production, are likely to reduce the progression of ventricular dysfunction in patients with ischemic cardiomyopathy.

Original languageEnglish
Pages (from-to)27-29
Number of pages3
JournalHeart and Metabolism
Issue number38
Publication statusPublished - 2008

Fingerprint

Trimetazidine
Myocardial Ischemia
Cardiomyopathies
Ventricular Dysfunction
Coenzyme A
Coronary Artery Disease
Therapeutics

Keywords

  • Ischemic cardiomyopathy
  • Myocardial energy
  • Silent myocardial ischemia
  • Symptomatic myocardial ischemia
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Efficacy of Vastarel MR on silent and symptomatic myocardial ischemia. / Camitini, Giuseppe; Marazzi, Giuseppe; Rosano, Giuseppe.

In: Heart and Metabolism, No. 38, 2008, p. 27-29.

Research output: Contribution to journalArticle

@article{43e7609631fc4e76a5fc468c1a232cf1,
title = "Efficacy of Vastarel MR on silent and symptomatic myocardial ischemia",
abstract = "Despite advances in the medical treatment of myocardial ischemia, a large proportion of patients with coronary artery disease suffer from angina and have silent episodes of myocardial ischemia. Chronic repetitive ischemic episodes may lead to ischemic cardiomyopathy. Trimetazidine, the 3-ketoacyl coenzyme A thiolase inhibitor, is a metabolically active agent that is effective, whether alone or in combination with standard therapy, in reducing myocardial ischemia. It has been shown to reduce daily episodes of both silent and symptomatic myocardial ischemia. These effects, together with those of trimetazidine on myocardial energy production, are likely to reduce the progression of ventricular dysfunction in patients with ischemic cardiomyopathy.",
keywords = "Ischemic cardiomyopathy, Myocardial energy, Silent myocardial ischemia, Symptomatic myocardial ischemia, Trimetazidine",
author = "Giuseppe Camitini and Giuseppe Marazzi and Giuseppe Rosano",
year = "2008",
language = "English",
pages = "27--29",
journal = "Heart and Metabolism",
issn = "1566-0338",
publisher = "Imprimerie Jouve",
number = "38",

}

TY - JOUR

T1 - Efficacy of Vastarel MR on silent and symptomatic myocardial ischemia

AU - Camitini, Giuseppe

AU - Marazzi, Giuseppe

AU - Rosano, Giuseppe

PY - 2008

Y1 - 2008

N2 - Despite advances in the medical treatment of myocardial ischemia, a large proportion of patients with coronary artery disease suffer from angina and have silent episodes of myocardial ischemia. Chronic repetitive ischemic episodes may lead to ischemic cardiomyopathy. Trimetazidine, the 3-ketoacyl coenzyme A thiolase inhibitor, is a metabolically active agent that is effective, whether alone or in combination with standard therapy, in reducing myocardial ischemia. It has been shown to reduce daily episodes of both silent and symptomatic myocardial ischemia. These effects, together with those of trimetazidine on myocardial energy production, are likely to reduce the progression of ventricular dysfunction in patients with ischemic cardiomyopathy.

AB - Despite advances in the medical treatment of myocardial ischemia, a large proportion of patients with coronary artery disease suffer from angina and have silent episodes of myocardial ischemia. Chronic repetitive ischemic episodes may lead to ischemic cardiomyopathy. Trimetazidine, the 3-ketoacyl coenzyme A thiolase inhibitor, is a metabolically active agent that is effective, whether alone or in combination with standard therapy, in reducing myocardial ischemia. It has been shown to reduce daily episodes of both silent and symptomatic myocardial ischemia. These effects, together with those of trimetazidine on myocardial energy production, are likely to reduce the progression of ventricular dysfunction in patients with ischemic cardiomyopathy.

KW - Ischemic cardiomyopathy

KW - Myocardial energy

KW - Silent myocardial ischemia

KW - Symptomatic myocardial ischemia

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=42049088065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049088065&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:42049088065

SP - 27

EP - 29

JO - Heart and Metabolism

JF - Heart and Metabolism

SN - 1566-0338

IS - 38

ER -